RNTX

Rein Therapeutics Inc. (RNTX) | Rumor.io

Rein Therapeutics

RNTX

Attention (50-day avg)0%

Attention rank (50-day avg)#2,439

Bullish sentiment (50-day avg)41%

Price to earnings ratio-0.37

Market capitalization62.2M

Earnings per share-1.68

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-49.9M

Social

What share of all stock conversation is about RNTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% +0

Aug 20

The FDA granted Fast Track designation to LTI-03 for idiopathic pulmonary fibrosis, a disease that affects the lungs.
Rein Therapeutics' Phase 2 RENEW trial for LTI-03 is enrolling across five countries, with interim data expected in 2H 2026.
LTI-03 holds both U.S. Orphan Drug and Fast Track designations for IPF, a serious and rare disease with limited treatment options.

Generated by AI

Sentiment

Of the messages about RNTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +86.96	77.14% -21.44
Bearish	—	—	0% -86.96	22.86% +21.44

Jan 30

Rein Therapeutics Inc. (RNTX) is meeting expectations with its performance.
The company's stock is a good option for those looking to make a profit.
Investor sentiment is overwhelmingly positive, with many believing the stock will continue to perform well.

Generated by AI

Topics

Of the messages about RNTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	99.11%
Analysts	—	—	0%	0.15%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	0.74%

Nov 3

Rein Therapeutics Inc. ($RNTX) received FDA clearance to resume its U.S. Phase 2 trial of LTI-03 for Idiopathic Pulmonary Fibrosis.
The FDA lifted the full clinical hold, allowing the U.S. trial to resume, with plans to restart enrollment in late 2025/early 2026 across ~20 sites.
The company expects topline data from the trial in Q3 2026, reinforcing mid-term biotech visibility.

Generated by AI

Community

Of the messages about RNTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	91.67%	80.21%	8.32%
Newcomers	100%	8.33%	19.79%	91.68%

Aug 20

Newcomers to discussing $RNTX are focused on the recent FDA Fast Track Designation for LTI-03 in idiopathic pulmonary fibrosis, which may indicate a promising development for Rein Therapeutics.
The FDA Fast Track Designation is seen as a positive step for Rein Therapeutics, as it allows for faster review and potential approval of LTI-03, which could lead to increased investor interest in the company.
Interim data from the ongoing Phase 2 RENEW trial is expected in H2 2026, which may provide further insight into the efficacy of LTI-03 in treating idiopathic pulmonary fibrosis, a key area of focus for Rein Therapeutics.

Generated by AI

AUSTIN, Texas, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that it will present a late-breaking poster at the European Respiratory Society (ERS) 2026 Congress taking place September 5-9, 2026, in Barcelona, Spain. Poster Presentation Title: Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation s

26d agoYahoo Finance

Rein Therapeutics to Present at Upcoming September Investor Conferences

AUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, President and Chief Executive Officer of Rein Therapeutics, will present at the following investor conferences in September. 2026 Cantor Global Healthcare Conference Date & Time: Friday, September 11, 2026, at 8:00 a.m. ETLocation: New York,

26d agoYahoo Finance

Here's Why You Should Add RNTX Stock to Your Portfolio Now

Rein Therapeutics advances LTI-03 in IPF. RENEW enrollment tops 25%, with interim data expected in the fourth quarter of 2026.

26d agoYahoo Finance

Rein Therapeutics Receives Nasdaq Delisting Notice Over Bid Price

Tipranks Press Release.

1mo agoThe Globe and Mail

Rein Therapeutics receives FDA fast track for IPF drug LTI-03

1mo agoInvesting.com

Also Discussed

Investors talking about RNTX also mention

#	Name	Attention
1	VolitionRx LimitedVNRX	0%new
2	Captivision Inc.CAPT	0%new
3	Tharimmune Inc.THAR	0%new
4	TuHURA Biosciences, Inc.HURA	0%0
5	Os Therapies Inc.OSTX	0.1%+0.07
6	Above Food Ingredients Inc.ABVE	0%new
7	La Rosa Holdings Corp.LRHC	0%0
8	SQSP - Squarespace, Inc.	——
9	Algoma Steel Group Inc. Common SharesASTL	0%new
10	Avery Dennison CorporationAVY	0%0

Rein Therapeutics Inc.

Healthcare
Biotechnology

Rein Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for orphan pulmonary and fibrosis indications. The company’s current pipeline centers on LTI-03, a peptide being advanced for idiopathic pulmonary fibrosis, and LTI-01, a therapy candidate for loculated pleural effusion. Its portfolio also includes additional preclinical programs targeting fibrosis-related pathways and cystic fibrosis. Rein Therapeutics develops peptide-based and protein-based therapeutics designed to address serious diseases with limited treatment options, making it a specialized player in respiratory and fibrotic medicine. Headquartered in Austin, Texas, Rein Therapeutics serves the biopharmaceutical market through research, clinical development, and product advancement for highly targeted rare-disease applications.

Website

Location

12407 N. Mopac Expy.

Austin, TX, 78758

United States

Social

What share of all stock conversation is about RNTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% +0

Aug 20

The FDA granted Fast Track designation to LTI-03 for idiopathic pulmonary fibrosis, a disease that affects the lungs.
Rein Therapeutics' Phase 2 RENEW trial for LTI-03 is enrolling across five countries, with interim data expected in 2H 2026.
LTI-03 holds both U.S. Orphan Drug and Fast Track designations for IPF, a serious and rare disease with limited treatment options.

Generated by AI

Sentiment

Of the messages about RNTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +86.96	77.14% -21.44
Bearish	—	—	0% -86.96	22.86% +21.44

Jan 30

Rein Therapeutics Inc. (RNTX) is meeting expectations with its performance.
The company's stock is a good option for those looking to make a profit.
Investor sentiment is overwhelmingly positive, with many believing the stock will continue to perform well.

Generated by AI

Topics

Of the messages about RNTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	99.11%
Analysts	—	—	0%	0.15%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	0.74%

Nov 3

Rein Therapeutics Inc. ($RNTX) received FDA clearance to resume its U.S. Phase 2 trial of LTI-03 for Idiopathic Pulmonary Fibrosis.
The FDA lifted the full clinical hold, allowing the U.S. trial to resume, with plans to restart enrollment in late 2025/early 2026 across ~20 sites.
The company expects topline data from the trial in Q3 2026, reinforcing mid-term biotech visibility.

Generated by AI

Community

Of the messages about RNTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	91.67%	80.21%	8.32%
Newcomers	100%	8.33%	19.79%	91.68%

Aug 20

Newcomers to discussing $RNTX are focused on the recent FDA Fast Track Designation for LTI-03 in idiopathic pulmonary fibrosis, which may indicate a promising development for Rein Therapeutics.
The FDA Fast Track Designation is seen as a positive step for Rein Therapeutics, as it allows for faster review and potential approval of LTI-03, which could lead to increased investor interest in the company.
Interim data from the ongoing Phase 2 RENEW trial is expected in H2 2026, which may provide further insight into the efficacy of LTI-03 in treating idiopathic pulmonary fibrosis, a key area of focus for Rein Therapeutics.

Generated by AI

Rein Therapeutics

Social

Aug 20

Sentiment

Jan 30

Topics

Nov 3

Community

Aug 20

News

Rein Therapeutics at cantor global healthcare: ipf push gains traction

Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress

Rein Therapeutics to Present at Upcoming September Investor Conferences

Here's Why You Should Add RNTX Stock to Your Portfolio Now

Rein Therapeutics Receives Nasdaq Delisting Notice Over Bid Price

Rein Therapeutics receives FDA fast track for IPF drug LTI-03

Also Discussed

Rein Therapeutics Inc.

Company Information

Location

News

Rein Therapeutics at cantor global healthcare: ipf push gains traction

Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress

Rein Therapeutics to Present at Upcoming September Investor Conferences

Here's Why You Should Add RNTX Stock to Your Portfolio Now

Rein Therapeutics Receives Nasdaq Delisting Notice Over Bid Price

Rein Therapeutics receives FDA fast track for IPF drug LTI-03

Also Discussed

Social

Aug 20

Sentiment

Jan 30

Topics

Nov 3

Community

Aug 20